Condition
Intestinal Malabsorption
Total Trials
4
Recruiting
2
Active
2
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 55/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results50% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 2 (1)
P 3 (2)
Trial Status
Recruiting2
Terminated1
Completed1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05904626Phase 2RecruitingPrimary
Assess the Safety of ELGN-2112 in Preterm Infants Born Under 26 Weeks GA and IUGR Infants Born 26-32 Weeks GA
NCT05670951Phase 3RecruitingPrimary
Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants
NCT02510560Phase 3Terminated
Study to Assess the Efficacy and Safety of NTRA-2112 on Intestinal Malabsorption in Preterm Infants
NCT04791774Not ApplicableCompletedPrimary
Protein-bound Versus Free Amino Acid Nutrition During INtestinal Malabsorption in Critical Illness
Showing all 4 trials